The latest price target for Can Fite Biofarma (AMEX:CANF) was reported by HC Wainwright & Co. on November 12, 2024. The analyst firm set a price target for $18.00 expecting CANF to rise to within 12 months (a possible 769.57% upside). 6 analyst firms have reported ratings in the last year.

The latest analyst rating for Can Fite Biofarma (AMEX:CANF) was provided by HC Wainwright & Co., and Can Fite Biofarma reiterated their buy rating.

There is no last upgrade for Can Fite Biofarma

There is no last downgrade for Can Fite Biofarma.

Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Can Fite Biofarma, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Can Fite Biofarma was filed on November 12, 2024 so you should expect the next rating to be made available sometime around November 12, 2025.

While ratings are subjective and will change, the latest Can Fite Biofarma (CANF) rating was a reiterated with a price target of $18.00 to $18.00. The current price Can Fite Biofarma (CANF) is trading at is $2.07, which is out of the analyst’s predicted range.